ATOSSA THERAPEUTICS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ATOSSA THERAPEUTICS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2015 | $1.8K | Mar 21, 2017 |
| FY2015 | Dec 31, 2014 | $40.1K | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $632.6K | Mar 30, 2015 |
| FY2013 | Dec 31, 2012 | $481.8K | Mar 27, 2014 |
| FY2012 | Dec 31, 2011 | $1.5K | Mar 28, 2013 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2015 | ($130.7K) | Mar 21, 2017 |
| FY2015 | Dec 31, 2014 | $40.1K | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $137.1K | Mar 30, 2015 |
| FY2013 | Dec 31, 2012 | $416.2K | Mar 27, 2014 |
| FY2012 | Dec 31, 2011 | ($95.7K) | Mar 28, 2013 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($34.77M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($25.50M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($30.09M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($26.96M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($20.61M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($17.83M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($17.24M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($11.40M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($8.12M) | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | ($6.37M) | Mar 8, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($37.14M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($27.62M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($31.38M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($27.69M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($20.52M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($14.61M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($17.27M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($11.43M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($7.65M) | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | ($7.97M) | Mar 8, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.19M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $14.12M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $17.33M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $15.08M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $9.21M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $6.61M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $6.65M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $4.21M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $2.33M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $770.4K | Mar 8, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($29.76M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($21.03M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($20.94M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($20.76M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($16.47M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($11.57M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($9.13M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($8.96M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($6.59M) | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | ($5.37M) | Mar 8, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.0K | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $19.0K | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $14.0K | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $27.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $9.0K | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $9.0K | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $7.6K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $110.9K | Mar 26, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $47.61M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $76.44M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $96.25M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $123.53M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $141.26M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $42.84M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $14.49M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $11.72M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $8.16M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $4.14M | Mar 8, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.26M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $4.97M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $5.24M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $5.57M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $3.13M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $15.67M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $1.33M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $2.92M | Mar 26, 2020 |
| FY2016 | Dec 31, 2016 | $1.05M | Mar 21, 2017 |
| FY2016 | Dec 31, 2015 | $2.50M | Mar 21, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $39.35M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $71.48M | Mar 25, 2026 |
| FY2025 | Dec 31, 2023 | $91.02M | Mar 25, 2026 |
| FY2024 | Dec 31, 2022 | $117.96M | Mar 25, 2025 |
| FY2023 | Dec 31, 2021 | $138.14M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $27.17M | Mar 22, 2023 |
| FY2021 | Dec 31, 2019 | $13.16M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $8.81M | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $6.94M | Mar 26, 2020 |
| FY2018 | Dec 31, 2016 | $3.10M | Mar 28, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($246.56M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($211.79M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($186.29M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($156.19M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($129.23M) | Mar 22, 2023 |
| FY2021 | Jan 1, 2021 | ($108.63M) | Feb 28, 2022 |
| FY2021 | Dec 31, 2020 | ($111.90M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($94.07M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($76.83M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($65.43M) | Mar 28, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $41.30M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $71.08M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $88.46M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $110.89M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $136.38M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $39.55M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $12.58M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $10.38M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $7.22M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $3.03M | Mar 8, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 22, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8.61M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | 8.61M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | 125.30M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | 126.62M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 126.62M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | 47.55M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 9.13M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 5.85M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | 2.65M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | 3.79M | Mar 8, 2018 |